Novartis Investigative Site

Albuquerque, New Mexico 87131-5271

0 studies enrolling now · 26 studies all time

What they study most

Ankylosing Spondylitis, Atherosclerosis, Cardiovascular Disease, Chronic Myelogenous Leukemia, Chronic Obstructive Pulmonary Disease, Coronary Artery Disease (CAD), Coronary Atherosclerosis, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Leukaemia, Lymphocytic, Chronic, Major Depressive Disorder, Neoplasms, Breast

Studies at this site

• ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D — Completed
• Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) — Completed
• Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis — Completed
• Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. — Completed
• Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis — Completed
• Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD — Completed
• Study of Efficacy of PEAR-004 in Schizophrenia — Completed
• Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. — Completed
• Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder — Completed
• Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder — Completed
• Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer — Completed
• Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy — Stopped early
• Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis — Completed
• MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone — Stopped early
• Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy — Stopped early
• EXTEND (Eltrombopag Extended Dosing Study) — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early
• Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents. — Stopped early
• A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients — Completed
• NVA237 BID Versus Placebo Twelve-week Efficacy Study — Completed
• 3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs — Completed
• Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients — Completed
• Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early
• Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia — Completed